In refractory or relapsed AML, IDH1 (Ivosidenib) and IDH2 (Enasidenib) inhibitors have shown interesting results in monotherapy with response rates of 31% and 40%, respectively [95,96]. Here, IDH1 is linked to acute myeloid leukemia.